Evidence map›Paper›PMID 37803384›Full record

ArticleTrials2023

Antidepressants for the prevention of depression following first-episode psychosis (ADEPP): study protocol for a multi-centre, double-blind, randomised controlled trial.

Edward R Palmer, Siân Lowri Griffiths, Ben Watkins, Tyler Weetman, Ryan Ottridge, Smitaa Patel, Rebecca Woolley, Sarah Tearne, Pui Au, Eleanor Taylor and 13 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Efficacy of sertraline combined with low-dose antipsychotics in first-episode schizophrenia.European archives of psychiatry and clinical neuroscience · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 1 country.

Edward R PalmerInstitute for Mental Health, School of Psychology, University of Birmingham, Birmingham, UK.
Siân Lowri GriffithsInstitute for Mental Health, School of Psychology, University of Birmingham, Birmingham, UK.
Ben WatkinsBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Tyler WeetmanInstitute for Mental Health, School of Psychology, University of Birmingham, Birmingham, UK.
Ryan OttridgeBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Smitaa PatelBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Rebecca WoolleyBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Sarah TearneBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Pui AuBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Eleanor TaylorBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Zara SadiqEarly Intervention Service, Birmingham Women's and Children's NHS Trust, Birmingham, UK.
Hareth Al-JanabiHealth Economics Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Barnaby MajorHerefordshire and Worcestershire Health and Care NHS Trust, Worcester, UK.
Charlotte MarriottHerefordshire and Worcestershire Health and Care NHS Trust, Worcester, UK.
Nusrat HusainDivision of Psychology and Mental Health, University of Manchester, Manchester, UK.
Mohammad Zia Ul Haq KatshuInstitute of Mental Health, Division of Mental Health and Neurosciences University of Nottingham, Nottingham, UK.
Domenico GiaccoDivision of Health Sciences, Warwick Medical School, University of Warwick, Warwick, UK.
Nicholas M BarnesInstitute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
James T R WaltersCentre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, Wales, UK.
Thomas R E BarnesDivision of Psychiatry, Imperial College London, London, UK.
Max BirchwoodDivision of Health Sciences, Warwick Medical School, University of Warwick, Warwick, UK.
Richard DrakeDivision of Psychology and Mental Health, University of Manchester, Manchester, UK.
Rachel UpthegroveInstitute for Mental Health, School of Psychology, University of Birmingham, Birmingham, UK. r.upthegrove@bham.ac.uk.ORCID http://orcid.org/0000-0001-8204-5103
Cancer Research UK Clinical Trials Unit · GBBirmingham Women’s and Children’s NHS Foundation Trust · GBUniversity of Birmingham · GBUniversity of Manchester · GBUniversity of Warwick · GBWorcestershire Health and Care NHS Trust · GBBirmingham and Solihull Mental Health NHS Foundation Trust · GBCardiff University · GBImperial College London · GBNational Health Service · GB

Funding

Medical Research Council MR/L010305/1Medical Research Council MR/S037675/1
6 · The paper itself

Abstract

backgroundDepressive episodes are common after first-episode psychosis (FEP), affecting more than 40% of people, adding to individual burden, poor outcomes, and healthcare costs. If the risks of developing depression were lower, this could have a beneficial effect on morbidity and mortality, as well as improving outcomes. Sertraline is a selective serotonin reuptake inhibitor and a common first-line medication for the treatment of depression in adults. It has been shown to be safe when co-prescribed with antipsychotic medication, and there is evidence that it is an effective treatment for depression in established schizophrenia. We present a protocol for a multi-centre, double-blind, randomised, placebo-controlled clinical trial called ADEPP that aims to investigate the efficacy and cost-effectiveness of sertraline in preventing depression after FEP.

methodsThe recruitment target is 452 participants between the ages of 18 and 65 years who are within 12 months of treatment initiation for FEP. Having provided informed consent, participants will be randomised to receive either 50 mg of sertraline daily or matched placebo for 6 months, in addition to treatment as usual. The primary outcome measure will be a comparison of the number of new cases of depression between the treatment and placebo arms over the 6-month intervention phase. Secondary outcomes include suicidal behaviour, anxiety, rates of relapse, functional outcome, quality of life, and resource use. DISCUSSION: The ADEPP trial will test whether the addition of sertraline following FEP is a clinically useful, acceptable, and cost-effective way of improving outcomes following FEP.

trial registrationISRCTN12682719 registration date 24/11/2020.

Indexed as

Psychotic DisordersSertralineAdultAntidepressive AgentsChild, PreschoolDepressionHumansInfantMulticenter Studies as TopicNeoplasm Recurrence, LocalQuality of LifeRandomized Controlled Trials as TopicTreatment OutcomeAntidepressive AgentsSertralineAntidepressantDepressionFirst-episode psychosisFunctioningPrevention

Identifiers

PMID37803384
PMCPMC10557320
OpenAlexW4387408129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.